; onclick=)
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?fit=800%2C600&ssl=1" class="aligncenter wp-post-image" alt="" decoding="async" srcset="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?w=800&ssl=1 800w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?resize=768%2C576&ssl=1 768w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?resize=360%2C270&ssl=1 360w, https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?resize=600%2C450&ssl=1 600w" sizes="(max-width: 800px) 100vw, 800px" data-attachment-id="255620" data-permalink="https://rxharun.com/rxharun/drug-a-z/clofarabine/attachment/clofarabine-uses-dosage-side-effects-interaction/" data-orig-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?fit=800%2C600&ssl=1" data-orig-size="800,600" data-comments-opened="0" data-image-meta="{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}" data-image-title="Clofarabine – Uses, Dosage, Side Effects, Interaction" data-image-description="" data-image-caption="" data-medium-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?fit=800%2C600&ssl=1" data-large-file="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?fit=800%2C600&ssl=1" data-jpibfi-post-excerpt="" data-jpibfi-post-url="https://rxharun.com/rxharun/drug-a-z/clofarabine/" data-jpibfi-post-title="Clofarabine – Uses, Dosage, Side Effects, Interaction" data-jpibfi-src="https://i0.wp.com/
Notice (8): Undefined index: api_key [APP/Controller/PageprocessController.php, line 111]
Notice (8): Undefined index: site_id [APP/Controller/PageprocessController.php, line 112]/wp-content/uploads/2023/06/clofarabine-uses-dosage-side-effects-interaction_245515.jpg?fit=800%2C600&ssl=1">
Clofarabine is a purine analog and antineoplastic agent used in the therapy of acute lymphoblastic leukemia (ALL) in children. Clofarabine is associated with frequent transient serum enzyme elevations during therapy, but they are usually asymptomatic and transient and it has only rarely been implicated in causing clinically apparent acute liver injury with jaundice.
Clofarabine is a second-generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5′-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in the inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pro-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.
Clofarabine is a purine nucleoside analog consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2′-deoxy-2′-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5′-triphosphate metabolite, which inhibits DNA synthesis is and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukemia. It has a role as an antineoplastic agent and an antimetabolite. It is an organofluorine compound and a member of adenosines.
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in pediatrics to treat a type of leukemia called relapsed or refractory acute lymphoblastic leukemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends the life expectancy. Its potential use in acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) has been investigated.
Mechanism of Action
Clofarabine is metabolized intracellularly to the active 5′-monophosphate metabolite by deoxycytidine kinase and 5′-triphosphate metabolite by mono- and di-phospho-kinases. This metabolite inhibits DNA synthesis through an inhibitory action on ribonucleotide reductase, and by terminating DNA chain elongation and inhibiting repair through competitive inhibition of DNA polymerases. This leads to the depletion of the intracellular deoxynucleotide triphosphate pool and the self-potentiation of clofarabine triphosphate incorporation into DNA, thereby intensifying the effectiveness of DNA synthesis inhibition. The affinity of clofarabine triphosphate for these enzymes is similar to or greater than that of deoxyadenosine triphosphate. In preclinical models, clofarabine has demonstrated the ability to inhibit DNA repair by incorporation into the DNA chain during the repair process. Clofarabine 5′-triphosphate also disrupts the integrity of the mitochondrial membrane, leading to the release of the pro-apoptotic mitochondrial proteins, cytochrome C, and apoptosis-inducing factor, leading to programmed cell death.
Clofarabine is a purine nucleoside antimetabolite that differs from other purine nucleoside analogs by the presence of chlorine in the purine ring and fluorine in the ribose moiety. Clofarabine seems to interfere with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by clofarabine, other effects also occur. Clofarabine prevents cells from making DNA and RNA by interfering with the synthesis of nucleic acids, thus stopping the growth of cancer cells.
Indications
- For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
- Treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis.
- Clofarabine is approved to treat Acute lymphoblastic leukemia that has recurred (come back) or is refractory (does not respond to treatment) in children and young adults aged 1 to 21 years who have already had at least two other types of treatment.
- Refractory Acute Lymphoblastic Leukemia (ALL)
- Refractory Acute Myeloid Leukemia (AML)
- Relapsed Acute Lymphoblastic Leukemia (ALL)
- Refractory Langerhans cell histiocytosis
Use in Cancer
Clofarabine is approved to treat:
- Acute lymphoblastic leukemia that has recurred (come back) or is refractory (does not respond to treatment) in children and young adults aged 1 to 21 years who have already had at least two other types of treatment.
Clofarabine is also being studied in the treatment of other types of cancer.
Contraindications
- a bacterial infection
- opportunistic fungal infection
- dehydration
- decreased function of bone marrow
- anemia
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- capillary leak syndrome, is a condition where fluid leaks out of small blood vessels
- low blood pressure
- bleeding
- inflammation of the small and large intestine
- liver problems
- the high amount of bilirubin in the blood
- abnormal liver function tests
- pregnancy
- a patient who is producing milk and breastfeeding
- sepsis
- chronic kidney disease stage 3A (moderate)
- chronic kidney disease stage 3B (moderate)
- an increased risk of developing an uncommon viral infection called an opportunistic infection
Dosage
Strengths: 1 mg/mL
Acute Lymphoblastic Leukemia
18 to less than 22 years:
- 52 mg/m2 IV over 2 hours daily for 5 consecutive days of a 28-day cycle; repeat every 2 to 6 weeks
- Subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle.
- Subsequent cycles may be administered when the ANC is greater than or equal to 750/mm3.
- Provide supportive care, such as IV fluids, antihyperuricemics, and alkalinization of urine throughout therapy to reduce the risk of tumor lysis and other adverse events.
- Monitor renal, hepatic, and cardiac function during therapy.
- Monitor patients taking medications known to affect blood pressure.
- Discontinue therapy if hypotension develops during the 5 days of administration.
Acute Lymphoblastic Leukemia
1 year and older:
- 52 mg/m2 IV over 2 hours daily for 5 consecutive days of a 28-day cycle; repeat every 2 to 6 weeks
- Subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle.
- Subsequent cycles may be administered when the ANC is greater than or equal to 750/mm3.
- Provide supportive care, such as IV fluids, antihyperuricemics, and alkalinization of urine throughout therapy to reduce the risk of tumor lysis and other adverse events.
- Monitor renal, hepatic, and cardiac function during therapy.
- Monitor patients taking medications known to affect blood pressure.
- Discontinue therapy if hypotension develops during the 5 days of administration.
Renal Dose Adjustments
- Mild renal dysfunction (CrCl 60 to less than 90 mL/min): No adjustment is recommended.
- Moderate renal dysfunction (CrCl 30 to less than 60 mL/min): Reduce the starting dose by 50%.
- Severe renal dysfunction (CrCl less than 15 to less than 30 mL/min) and end-stage renal disease (CrCl less than 15 mL/min): Data not available
Dose Adjustments
Supportive Medications and Medications to Avoid:
- Consider prophylactic antiemetic medications as this drug is moderately emetogenic.
- Consider the use of prophylactic steroids to mitigate Systemic Inflammatory Response Syndrome (SIRS) or capillary leak syndrome (e.g., hypotension, tachycardia, tachypnea, pulmonary edema).
- Minimize exposure to drugs with known renal toxicity during the 5 days of therapy since the risk of renal toxicity may be increased.
- Consider avoiding the concomitant use of medications known to induce hepatic toxicity.
Dose Modifications and Reinitiation of Therapy:
HEMATOLOGIC TOXICITY:
- Administer subsequent cycles no sooner than 14 days from the starting day of the previous cycle and provided the patient ANC is 0.75 x 10(9)/L or greater.
- If a patient experiences Grade 4 neutropenia (ANC less than 0.5 x 10(9)/L) lasting 4 weeks or more, reduce the dose by 25% for the next cycle.
NONHEMATOLOGIC TOXICITY:
- Withhold therapy if the patient develops a clinically significant infection, until the infection is controlled, then restart at the full dose.
- Withhold therapy for Grade 3 noninfectious nonhematologic toxicity (excluding transient elevations in serum transaminases and/or serum bilirubin and/or nausea/vomiting controlled by antiemetic therapy); reinstitute therapy at a 25% dose reduction with resolution or return to baseline.
- Discontinue therapy for Grade 4 noninfectious nonhematologic toxicity.
- Discontinue therapy if a patient shows early signs or symptoms of SIRS or capillary leak (e.g., hypotension, tachycardia, tachypnea, pulmonary edema) occur, and provide supportive measures.
- Discontinue therapy if Grade 3 or higher increases in creatinine or bilirubin are noted; reinstitute therapy at a 25% dose reduction, when the patient is stable and organ function has returned to baseline. If hyperuricemia is anticipated (tumor lysis), initiate measures to control uric acid.
Side Effects
The Most Common
- nausea
- vomiting
- stomach pain
- diarrhea
- constipation
- loss of appetite
- weight loss
- swelling of the inside of the mouth and nose
- painful white patches in the mouth
- headache
- anxiety
- depression
- irritability
- pain in the back, joints, arms, or legs
- drowsiness
- dry, itchy, or irritated skin
- flushing
- fast heartbeat
- fast breathing
- shortness of breath
- dizziness
- lightheadedness
- fainting
- decreased urination
- sore throat, cough, fever, chills, and other signs of infection
- pale skin
- excessive tiredness
- weakness
- confusion
- unusual bruising or bleeding
- nosebleed
- bleeding gums
- blood in urine
- small red or purple spots under the skin
- yellowing of the skin or eyes
- itching
- red, warm, swollen, tender skin
- uncontrollable shaking of a part of the body
More Common
- Tumor lysis syndrome (TLS). Clofarabine quickly kills leukemia cells in the blood. The body may react to this. Signs include hyperkalemia, hyperuricemia, and hyperphosphatemia. TLS is very serious and can lead to death if it is not treated right away.
- Systemic inflammatory response syndrome (SIRS): symptoms include fast breathing, fast heartbeat, low blood pressure, and fluid in the lungs.
- Bone marrow problems (suppression). Clofarabine can stop the bone marrow from making enough red blood cells, white blood cells, and platelets. Serious side effects that can happen because of bone marrow suppression include severe infection (sepsis), bleeding, and anemia.
- Effects on pregnancy and breastfeeding. Girls and women should not become pregnant or breastfeed during treatment which may harm the baby.
- Dehydration and low blood pressure. Clofarabine can cause vomiting and diarrhea which may lead to low body fluid (dehydration). Signs and symptoms of dehydration include dizziness, lightheadedness, fainting spells, or decreased urination.
- Other side effects. The most common side effects are stomach problems (including vomiting, diarrhea, and nausea), and effects on blood cells (including low red blood cells count, low white blood cell count, low platelet count, fever, and infection). Clofarabine can also cause tachycardia and can affect the liver and kidneys.
- trouble breathing while lying down;
- diarrhea that is watery or bloody;
- little or no urination;
- pain, blisters, bleeding, or severe rash on the palms of your hands or the soles of your feet;
- low blood pressure–a light-headed feeling, like you might pass out;
- signs of a liver problem–upper stomach pain, sudden swelling in your mid-section, dark urine, jaundice (yellowing of the skin or eyes);
- signs of infection–fever, chills, tiredness, mouth and throat ulcers, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, shallow breathing;
- signs of bleeding inside the body–sudden numbness or weakness (especially on one side of the body), severe headache, problems with vision or speech, chest pain, coughing up blood, blood in your urine, bloody or tarry stools; or
- signs of tumor cell breakdown–tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth.
Rare
- loss of appetite
- mouth sores, sore throat
- muscle aches
- nausea
- pain, redness or blistering of hands and feet
- rash
- sleepiness
- vomiting
- weakness
- changes in blood pressure
- diarrhea, nausea, and vomiting lasting more than 24 hours
- the feeling of being unwell
- fluid accumulating in the lungs (e.g., shortness of breath, rapid breathing, chest pain)
- muscle and joint pain
- inflammation in the digestive system (e.g., abdominal pain, fever, vomiting, diarrhea)
- rapid heartbeat
- shortness of breath
- signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath)
- signs of bleeding (e.g., bloody nose, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding)
- signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide)
- signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools)
- signs of fluid gathering around the heart (e.g., chest pain, shortness of breath when lying down, painful breathing, fainting, dizziness)
- signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness)
- signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat)
- signs of severe bleeding (e.g., vomit resembling coffee grounds in texture and color, black tarry stools)
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abacavir | Clofarabine may decrease the excretion rate of Abacavir which could result in a higher serum level. |
| Abatacept | The risk or severity of adverse effects can be increased when Clofarabine is combined with Abatacept. |
| Abciximab | The risk or severity of bleeding can be increased when Abciximab is combined with Clofarabine. |
| Abemaciclib | Abemaciclib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Acebutolol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Acebutolol. |
| Aceclofenac | Aceclofenac may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Acemetacin | Acemetacin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Acenocoumarol is combined with Clofarabine. |
| Acetaminophen | Acetaminophen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Acetazolamide | Acetazolamide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Acetylsalicylic acid | The excretion of Clofarabine can be decreased when combined with Acetylsalicylic acid. |
| Aclidinium | Clofarabine may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
| Acrivastine | Clofarabine may decrease the excretion rate of Acrivastine which could result in a higher serum level. |
| Acyclovir | The excretion of Clofarabine can be decreased when combined with Acyclovir. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Clofarabine. |
| Adefovir dipivoxil | Adefovir dipivoxil may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Adenovirus type | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Clofarabine. |
| Afatinib | Afatinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Albutrepenonacog alfa | Clofarabine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. |
| Alclofenac | Alclofenac may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clofarabine. |
| Alectinib | Alectinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Clofarabine. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clofarabine. |
| Aliskiren | The risk or severity of adverse effects can be increased when Clofarabine is combined with Aliskiren. |
| Allogeneic processed | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Clofarabine. |
| Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Clofarabine. |
| Almasilate | Clofarabine may decrease the excretion rate of Almasilate which could result in a higher serum level. |
| Almotriptan | Clofarabine may decrease the excretion rate of Almotriptan which could result in a higher serum level. |
| Alogliptin | Clofarabine may decrease the excretion rate of Alogliptin which could result in a higher serum level. |
| Alprazolam | Alprazolam may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Clofarabine. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Clofarabine. |
| Amantadine | The serum concentration of Clofarabine can be increased when it is combined with Amantadine. |
| Ambrisentan | Clofarabine may increase the hypotensive activities of Ambrisentan. |
| Amifostine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Amifostine. |
| Amikacin | Clofarabine may decrease the excretion rate of Amikacin which could result in a higher serum level. |
| Amiloride | The serum concentration of Clofarabine can be increased when it is combined with Amiloride. |
| Aminohippuric acid | The serum concentration of Clofarabine can be increased when it is combined with Aminohippuric acid. |
| Aminophenazone | Aminophenazone may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Amiodarone | The serum concentration of Clofarabine can be increased when it is combined with Amiodarone. |
| Amitriptyline | Amitriptyline may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Amlodipine | The risk or severity of adverse effects can be increased when Amlodipine is combined with Clofarabine. |
| Ammonium chloride | Clofarabine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. |
| Amobarbital | Amobarbital may increase the hypotensive activities of Clofarabine. |
| Amoxicillin | Clofarabine may decrease the excretion rate of Amoxicillin which could result in a higher serum level. |
| Amphetamine | Amphetamine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Amphotericin B | The risk or severity of adverse effects can be increased when Clofarabine is combined with Amphotericin B. |
| Ampicillin | Ampicillin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Amrinone | Clofarabine may decrease the excretion rate of Amrinone which could result in a higher serum level. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Clofarabine. |
| Amyl Nitrite | The risk or severity of adverse effects can be increased when Clofarabine is combined with Amyl Nitrite. |
| Anagrelide | The risk or severity of bleeding can be increased when Anagrelide is combined with Clofarabine. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Clofarabine. |
| Ancestim | Clofarabine may decrease the excretion rate of Ancestim which could result in a higher serum level. |
| Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Clofarabine. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Anifrolumab. |
| Anistreplase | The risk or severity of bleeding can be increased when Anistreplase is combined with Clofarabine. |
| Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Clofarabine. |
| Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Clofarabine. |
| Antihemophilic | Clofarabine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Clofarabine is combined with Antilymphocyte immunoglobulin (horse). |
| Antipyrine | Antipyrine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Clofarabine. |
| Antithrombin III human | Clofarabine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clofarabine. |
| Antrafenine | Antrafenine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Apalutamide | The serum concentration of Clofarabine can be increased when it is combined with Apalutamide. |
| Apixaban | The risk or severity of bleeding can be increased when Apixaban is combined with Clofarabine. |
| Apomorphine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Apomorphine. |
| Apremilast | The risk or severity of adverse effects can be increased when Clofarabine is combined with Apremilast. |
| Ardeparin | The risk or severity of bleeding can be increased when Ardeparin is combined with Clofarabine. |
| Arformoterol | Clofarabine may decrease the excretion rate of Arformoterol which could result in a higher serum level. |
| Argatroban | The risk or severity of bleeding can be increased when Argatroban is combined with Clofarabine. |
| Aripiprazole | Aripiprazole may increase the hypotensive activities of Clofarabine. |
| Aripiprazole lauroxil | Aripiprazole lauroxil may increase the hypotensive activities of Clofarabine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Articaine. |
| COVID-19 Vaccine | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Clofarabine. |
| Ataluren | The excretion of Clofarabine can be decreased when combined with Ataluren. |
| Atazanavir | Atazanavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Atenolol | The risk or severity of adverse effects can be increased when Atenolol is combined with Clofarabine. |
| Atomoxetine | Atomoxetine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Auranofin | Clofarabine may decrease the excretion rate of Auranofin which could result in a higher serum level. |
| Aurothioglucose | Clofarabine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. |
| Avanafil | Avanafil may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Avatrombopag | The excretion of Clofarabine can be decreased when combined with Avatrombopag. |
| Azacitidine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Azacitidine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Azathioprine. |
| Azelaic acid | Azelaic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Clofarabine is combined with Azilsartan medoxomil. |
| Aztreonam | Aztreonam may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Bacillus | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Clofarabine. |
| BCG-I live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Clofarabine. |
| Bacillus | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Clofarabine. |
| Bacitracin | Bacitracin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Baclofen | Baclofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Balsalazide | Balsalazide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Baricitinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Baricitinib. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Clofarabine. |
| Belatacept | The risk or severity of adverse effects can be increased when Clofarabine is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Belimumab. |
| Belinostat | The risk or severity of adverse effects can be increased when Clofarabine is combined with Belinostat. |
| Belumosudil | The risk or severity of adverse effects can be increased when Clofarabine is combined with Belumosudil. |
| Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Clofarabine. |
| Benazepril | The risk or severity of adverse effects can be increased when Benazepril is combined with Clofarabine. |
| Bendamustine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Bendamustine. |
| Bendroflumethiazide | Bendroflumethiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Benorilate | Benorilate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Benoxaprofen | Benoxaprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Benserazide | Clofarabine may decrease the excretion rate of Benserazide which could result in a higher serum level. |
| Benzatropine | Benzatropine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Benznidazole | Clofarabine may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Benzocaine. |
| Benzoic acid | The excretion of Clofarabine can be decreased when combined with Benzoic acid. |
| Benzthiazide | Benzthiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Benzydamine | Benzydamine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Benzyl alcohol. |
| Benzylpenicillin | The excretion of Clofarabine can be decreased when combined with Benzylpenicillin. |
| Bepotastine | Clofarabine may decrease the excretion rate of Bepotastine which could result in a higher serum level. |
| Bepridil | The risk or severity of adverse effects can be increased when Clofarabine is combined with Bepridil. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Clofarabine. |
| Betaxolol | The risk or severity of adverse effects can be increased when Betaxolol is combined with Clofarabine. |
| Bethanidine | Clofarabine may increase the hypotensive activities of Bethanidine. |
| Betrixaban | The risk or severity of bleeding can be increased when Betrixaban is combined with Clofarabine. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Clofarabine. |
| Bicisate | Clofarabine may decrease the excretion rate of Bicisate which could result in a higher serum level. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Bimekizumab. |
| Bismuth subgallate | Clofarabine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. |
| Bisoprolol | The risk or severity of adverse effects can be increased when Bisoprolol is combined with Clofarabine. |
| Bisoxatin | Clofarabine may decrease the excretion rate of Bisoxatin which could result in a higher serum level. |
| Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Clofarabine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Clofarabine. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Blinatumomab. |
| Bordetella pertussis | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Clofarabine. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Clofarabine. |
| Bosentan | Clofarabine may increase the hypotensive activities of Bosentan. |
| Bosutinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Bosutinib. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Brentuximab vedotin. |
| Bretylium | The risk or severity of adverse effects can be increased when Clofarabine is combined with Bretylium. |
| Brigatinib | Brigatinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Brivaracetam | Clofarabine may decrease the excretion rate of Brivaracetam which could result in a higher serum level. |
| Brodalumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Brodalumab. |
| Bromazepam | Clofarabine may decrease the excretion rate of Bromazepam which could result in a higher serum level. |
| Bromocriptine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Bromocriptine. |
| Bromotheophylline | Bromotheophylline may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Budesonide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Budesonide. |
| Bumadizone | Bumadizone may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Bumetanide | The excretion of Clofarabine can be decreased when combined with Bumetanide. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Bupivacaine. |
| Buprenorphine | Buprenorphine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Bupropion | The serum concentration of Clofarabine can be increased when it is combined with Bupropion. |
| Buspirone | Buspirone may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Busulfan | The risk or severity of adverse effects can be increased when Clofarabine is combined with Busulfan. |
| Butabarbital | Butabarbital may increase the hypotensive activities of Clofarabine. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Butacaine. |
| Butalbital | Butalbital may increase the hypotensive activities of Clofarabine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Butamben. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Clofarabine is combined with Cabazitaxel. |
| Cabotegravir | The excretion of Clofarabine can be decreased when combined with Cabotegravir. |
| Caffeine | Caffeine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Canagliflozin | Canagliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Canakinumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Canakinumab. |
| Candesartan | The risk or severity of adverse effects can be increased when Clofarabine is combined with Candesartan cilexetil. |
| Cangrelor | The risk or severity of bleeding can be increased when Cangrelor is combined with Clofarabine. |
| Cannabidiol | Cannabidiol may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Canrenoic acid | Canrenoic acid may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Capecitabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Capecitabine. |
| Caplacizumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Clofarabine. |
| Capmatinib | The serum concentration of Clofarabine can be increased when it is combined with Capmatinib. |
| Capreomycin | Clofarabine may decrease the excretion rate of Capreomycin which could result in a higher serum level. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Capsaicin. |
| Captopril | The risk or severity of adverse effects can be increased when Clofarabine is combined with Captopril. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with Clofarabine. |
| Carbetocin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Carbetocin. |
| Carbidopa | Carbidopa may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Carboplatin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Carboplatin. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Carfilzomib. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Clofarabine. |
| Carprofen | Carprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Carvedilol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Carvedilol. |
| Cefaclor | The excretion of Clofarabine can be decreased when combined with Cefaclor. |
| Cefadroxil | The excretion of Clofarabine can be decreased when combined with Cefadroxil. |
| Cefalotin | The excretion of Clofarabine can be decreased when combined with Cefalotin. |
| Cefamandole | The excretion of Clofarabine can be decreased when combined with Cefamandole. |
| Cefapirin | Cefapirin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefazolin | The excretion of Clofarabine can be decreased when combined with Cefazolin. |
| Cefdinir | Cefdinir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefditoren | Cefditoren may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefepime | Cefepime may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefmenoxime | Cefmenoxime may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefmetazole | Cefmetazole may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefonicid | Cefonicid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefoperazone | The excretion of Clofarabine can be decreased when combined with Cefoperazone. |
| Ceforanide | Ceforanide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefotaxime | The excretion of Clofarabine can be decreased when combined with Cefotaxime. |
| Cefotetan | Cefotetan may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefotiam | The excretion of Clofarabine can be decreased when combined with Cefotiam. |
| Cefoxitin | Cefoxitin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefpiramide | Cefpiramide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefpirome | Cefpirome may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefpodoxime | Cefpodoxime may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefprozil | Cefprozil may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cefradine | Cefradine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ceftaroline fosamil | Ceftaroline fosamil may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ceftazidime | Ceftazidime may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ceftibuten | The excretion of Clofarabine can be decreased when combined with Ceftibuten. |
| Ceftizoxime | The excretion of Clofarabine can be decreased when combined with Ceftizoxime. |
| Ceftobiprole | Ceftobiprole may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ceftolozane | Clofarabine may decrease the excretion rate of Ceftolozane which could result in a higher serum level. |
| Ceftriaxone | The excretion of Clofarabine can be decreased when combined with Ceftriaxone. |
| Cefuroxime | Cefuroxime may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Celecoxib | Celecoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Celiprolol | Clofarabine may increase the hypotensive activities of Celiprolol. |
| Cephalexin | The excretion of Clofarabine can be decreased when combined with Cephalexin. |
| Cephaloglycin | Cephaloglycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Certolizumab pegol. |
| Cetirizine | Cetirizine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cevimeline | Cevimeline may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Chloral hydrate | Clofarabine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Clofarabine. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Clofarabine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Chloroprocaine. |
| Chloroquine | Chloroquine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Chlorothiazide | Chlorothiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Chloroxylenol | Clofarabine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. |
| Chlorpheniramine | The serum concentration of Clofarabine can be increased when it is combined with Chlorpheniramine. |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Clofarabine. |
| Chlorpropamide | Clofarabine may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. |
| Chlorthalidone | Chlorthalidone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Chlorzoxazone | Chlorzoxazone may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cholesterol | Cholesterol may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Cholic Acid | The excretion of Clofarabine can be decreased when combined with Cholic Acid. |
| Choline | The serum concentration of Clofarabine can be increased when it is combined with Choline. |
| Choline C 11 | Clofarabine may decrease the excretion rate of Choline C 11 which could result in a higher serum level. |
| Choline magnesium | Choline magnesium trisalicylate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Choline salicylate | The serum concentration of Clofarabine can be increased when it is combined with Choline salicylate. |
| Chondroitin sulfate | Clofarabine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. |
| Chromic chloride | Clofarabine may decrease the excretion rate of Chromic chloride which could result in a higher serum level. |
| Chromic nitrate | Clofarabine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. |
| Chromium | Clofarabine may decrease the excretion rate of Chromium which could result in a higher serum level. |
| Chromium gluconate | Clofarabine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. |
| Chromium nicotinate | Clofarabine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. |
| Chromous sulfate | Clofarabine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. |
| Ciclesonide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ciclesonide. |
| Cidofovir | Cidofovir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cilastatin | The excretion of Clofarabine can be decreased when combined with Cilastatin. |
| Cilazapril | The risk or severity of adverse effects can be increased when Clofarabine is combined with Cilazapril. |
| Cilostazol | The risk or severity of bleeding can be increased when Cilostazol is combined with Clofarabine. |
| Cimetidine | The serum concentration of Clofarabine can be increased when it is combined with Cimetidine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Cinchocaine. |
| Ciprofloxacin | Ciprofloxacin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Clofarabine. |
| Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Clofarabine. |
| Clevidipine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Clevidipine. |
| Clobazam | Clobazam may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Clofarabine is combined with Clobetasol propionate. |
| Clofazimine | Clofazimine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Clomipramine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Clomipramine. |
| Clonazepam | Clofarabine may decrease the excretion rate of Clonazepam which could result in a higher serum level. |
| Clonidine | The risk or severity of adverse effects can be increased when Clonidine is combined with Clofarabine. |
| Clopidogrel | The serum concentration of Clofarabine can be increased when it is combined with Clopidogrel. |
| Clorazepic acid | Clorazepic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Clostridium tetani | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clofarabine. |
| Clove oil | Clofarabine may decrease the excretion rate of Clove oil which could result in a higher serum level. |
| Clozapine | The risk or severity of neutropenia can be increased when Clofarabine is combined with Clozapine. |
| Cobicistat | Cobicistat may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Cocaine. |
| Colchicine | Clofarabine may decrease the excretion rate of Colchicine which could result in a higher serum level. |
| Colistimethate | Colistimethate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Colistin | Clofarabine may decrease the excretion rate of Colistin which could result in a higher serum level. |
| Conivaptan | Conivaptan may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Conjugated estrogens | The excretion of Clofarabine can be decreased when combined with Conjugated estrogens. |
| Corifollitropin alfa | Clofarabine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. |
| Corticotropin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Clofarabine is combined with Cortisone acetate. |
| Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Clofarabine. |
| Crizotinib | The serum concentration of Clofarabine can be increased when it is combined with Crizotinib. |
| Cryptenamine | Clofarabine may increase the hypotensive activities of Cryptenamine. |
| Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Clofarabine. |
| Cyclopenthiazide | Cyclopenthiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Clofarabine. |
| Cyclosporine | Clofarabine may increase the immunosuppressive activities of Cyclosporine. |
| Cyclothiazide | Cyclothiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Cytarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Cytarabine. |
| Dabigatran | The risk or severity of bleeding can be increased when Dabigatran is combined with Clofarabine. |
| Dabigatran etexilate | Clofarabine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. |
| Dabrafenib | The serum concentration of Clofarabine can be increased when it is combined with Dabrafenib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dacarbazine. |
| Daclatasvir | Daclatasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Dacomitinib | Dacomitinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dactinomycin. |
| Dalfampridine | Clofarabine may decrease the excretion rate of Dalfampridine which could result in a higher serum level. |
| Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Clofarabine. |
| Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Clofarabine. |
| Dapagliflozin | Dapagliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Daptomycin | Daptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Clofarabine. |
| Darolutamide | Darolutamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Dasabuvir | Dasabuvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Dasatinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dasatinib. |
| Dasiglucagon | Clofarabine may increase the hypotensive activities of Dasiglucagon. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Daunorubicin. |
| Debrisoquine | Clofarabine may increase the hypotensive activities of Debrisoquine. |
| Decitabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Decitabine. |
| Deferiprone | Clofarabine may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
| Defibrotide | The risk or severity of bleeding can be increased when Defibrotide is combined with Clofarabine. |
| Deflazacort | The risk or severity of adverse effects can be increased when Clofarabine is combined with Deflazacort. |
| Delafloxacin | Clofarabine may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Clofarabine. |
| Deserpidine | Clofarabine may increase the hypotensive activities of Deserpidine. |
| Desflurane | The risk or severity of adverse effects can be increased when Clofarabine is combined with Desflurane. |
| Desipramine | The serum concentration of Clofarabine can be increased when it is combined with Desipramine. |
| Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Clofarabine. |
| Desmopressin | Desmopressin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Clofarabine. |
| Desvenlafaxine | Clofarabine may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. |
| Deucravacitinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Deucravacitinib. |
| Deutetrabenazine | Clofarabine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dexamethasone. |
| Dexamethasone acetate | Dexamethasone acetate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Dexchlorpheniramine | The serum concentration of Clofarabine can be increased when it is combined with Dexchlorpheniramine maleate. |
| Dexibuprofen | Dexibuprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Dexketoprofen | Dexketoprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dexmedetomidine. |
| Dexpanthenol | Clofarabine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Clofarabine. |
| Dextran | Clofarabine may decrease the excretion rate of Dextran which could result in a higher serum level. |
| Diatrizoate | Diatrizoate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Diazepam | Clofarabine may decrease the excretion rate of Diazepam which could result in a higher serum level. |
| Diazoxide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Diazoxide. |
| Dichlorobenzyl alcohol | Clofarabine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. |
| Diclofenac | The excretion of Clofarabine can be decreased when combined with Diclofenac. |
| Diclofenamide | Diclofenamide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Dicoumarol | The risk or severity of bleeding can be increased when Dicoumarol is combined with Clofarabine. |
| Dicyclomine | Clofarabine may decrease the excretion rate of Dicyclomine which could result in a higher serum level. |
| Didanosine | Clofarabine may decrease the excretion rate of Didanosine which could result in a higher serum level. |
| Dienogest | Clofarabine may decrease the excretion rate of Dienogest which could result in a higher serum level. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Diflunisal | Diflunisal may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Difluocortolone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Difluocortolone. |
| Digoxin | Clofarabine may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Dihydralazine | Clofarabine may increase the hypotensive activities of Dihydralazine. |
| Dihydrostreptomycin | Dihydrostreptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Diltiazem | The risk or severity of adverse effects can be increased when Diltiazem is combined with Clofarabine. |
| Dimercaprol | Clofarabine may decrease the excretion rate of Dimercaprol which could result in a higher serum level. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dimethyl fumarate. |
| Dimethyl sulfoxide | Clofarabine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. |
| Dinoprostone | The serum concentration of Clofarabine can be increased when it is combined with Dinoprostone. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dinutuximab. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Diphenhydramine. |
| Dipyridamole | The risk or severity of adverse effects can be increased when Clofarabine is combined with Dipyridamole. |
| Diroximel fumarate | The risk or severity of adverse effects can be increased when Clofarabine is combined with Diroximel fumarate. |
| Disopyramide | The serum concentration of Clofarabine can be increased when it is combined with Disopyramide. |
| DL-Methylephedrine | Clofarabine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. |
| Dobutamine | Clofarabine may decrease the excretion rate of Dobutamine which could result in a higher serum level. |
| Docetaxel | The risk or severity of adverse effects can be increased when Clofarabine is combined with Docetaxel. |
| Dolutegravir | The serum concentration of Clofarabine can be increased when it is combined with Dolutegravir. |
| Dopamine | The serum concentration of Clofarabine can be increased when it is combined with Dopamine. |
| Doripenem | Clofarabine may decrease the excretion rate of Doripenem which could result in a higher serum level. |
| Doxacurium | Clofarabine may decrease the excretion rate of Doxacurium which could result in a higher serum level. |
| Doxazosin | The risk or severity of adverse effects can be increased when Doxazosin is combined with Clofarabine. |
| Doxepin | Clofarabine may decrease the excretion rate of Doxepin which could result in a higher serum level. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Doxorubicin. |
| Doxycycline | Doxycycline may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Dronedarone | The serum concentration of Clofarabine can be increased when it is combined with Dronedarone. |
| Drospirenone | Drospirenone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Clofarabine. |
| Droxidopa | Clofarabine may decrease the excretion rate of Droxidopa which could result in a higher serum level. |
| Duloxetine | The risk or severity of orthostatic hypotension and syncope can be increased when Clofarabine is combined with Duloxetine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Dyclonine. |
| Dyphylline | Clofarabine may decrease the excretion rate of Dyphylline which could result in a higher serum level. |
| Ebola Zaire vaccine | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Clofarabine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Eculizumab. |
| Edetic acid | The risk or severity of bleeding can be increased when Edetic acid is combined with Clofarabine. |
| Edoxaban | Clofarabine may decrease the excretion rate of Edoxaban which could result in a higher serum level. |
| Edrophonium | Clofarabine may decrease the excretion rate of Edrophonium which could result in a higher serum level. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Clofarabine. |
| Elbasvir | Elbasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Eltrombopag | Eltrombopag may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Emapalumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Emapalumab. |
| Empagliflozin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Empagliflozin. |
| Enalapril | The excretion of Clofarabine can be decreased when combined with Enalapril. |
| Enalaprilat | The risk or severity of adverse effects can be increased when Clofarabine is combined with Enalaprilat. |
| Enasidenib | The serum concentration of Clofarabine can be increased when it is combined with Enasidenib. |
| Enoxaparin | The risk or severity of bleeding can be increased when Enoxaparin is combined with Clofarabine. |
| Enzalutamide | Clofarabine may decrease the excretion rate of Enzalutamide which could result in a higher serum level. |
| Epinephrine | The serum concentration of Clofarabine can be increased when it is combined with Epinephrine. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Clofarabine. |
| Eplerenone | Eplerenone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Epoprostenol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Epoprostenol. |
| Eprosartan | The risk or severity of adverse effects can be increased when Clofarabine is combined with Eprosartan. |
| Eptifibatide | The risk or severity of bleeding can be increased when Eptifibatide is combined with Clofarabine. |
| Erdafitinib | The serum concentration of Clofarabine can be increased when it is combined with Erdafitinib. |
| Eribulin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Eribulin. |
| Erlotinib | Erlotinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ertapenem | Ertapenem may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ertugliflozin | Ertugliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Clofarabine. |
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with Clofarabine. |
| Esomeprazole | The excretion of Clofarabine can be decreased when combined with Esomeprazole. |
| Estazolam | Clofarabine may decrease the excretion rate of Estazolam which could result in a higher serum level. |
| Estradiol | The serum concentration of Clofarabine can be increased when it is combined with Estradiol. |
| Estradiol acetate | The serum concentration of Clofarabine can be increased when it is combined with Estradiol acetate. |
| Estradiol benzoate | The serum concentration of Clofarabine can be increased when it is combined with Estradiol benzoate. |
| Estradiol cypionate | The serum concentration of Clofarabine can be increased when it is combined with Estradiol cypionate. |
| Estradiol dienanthate | The serum concentration of Clofarabine can be increased when it is combined with Estradiol dienanthate. |
| Estradiol valerate | The serum concentration of Clofarabine can be increased when it is combined with Estradiol valerate. |
| Estramustine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Estramustine. |
| Estrone sulfate | Clofarabine may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. |
| Eszopiclone | Eszopiclone may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Etacrynic acid | Etacrynic acid may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Etafedrine | Clofarabine may decrease the excretion rate of Etafedrine which could result in a higher serum level. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Clofarabine. |
| Ethambutol | Ethambutol may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ethanol | Ethanol may increase the hypotensive activities of Clofarabine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Etidocaine. |
| Etodolac | Etodolac may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Etomidate | Etomidate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Etonogestrel | Etonogestrel may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Etoposide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Etoposide. |
| Etoricoxib | Etoricoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Eucalyptus oil | Clofarabine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. |
| Everolimus | The risk or severity of adverse effects can be increased when Clofarabine is combined with Everolimus. |
| Ezogabine | Clofarabine may decrease the excretion rate of Ezogabine which could result in a higher serum level. |
| Famotidine | The serum concentration of Clofarabine can be increased when it is combined with Famotidine. |
| Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Clofarabine. |
| Favipiravir | The excretion of Clofarabine can be decreased when combined with Favipiravir. |
| Febuxostat | The excretion of Clofarabine can be decreased when combined with Febuxostat. |
| Fedratinib | Fedratinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Felodipine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Felodipine. |
| Fenbufen | Fenbufen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Fenofibrate | Clofarabine may decrease the excretion rate of Fenofibrate which could result in a higher serum level. |
| Fenofibric acid | Clofarabine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. |
| Fenoldopam | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fenoldopam. |
| Fenoprofen | Fenoprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Fentanyl | Clofarabine may decrease the excretion rate of Fentanyl which could result in a higher serum level. |
| Fesoterodine | Clofarabine may decrease the excretion rate of Fesoterodine which could result in a higher serum level. |
| Fexinidazole | The serum concentration of Clofarabine can be increased when it is combined with Fexinidazole. |
| Filgotinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Filgotinib. |
| Finerenone | Finerenone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Fingolimod | Clofarabine may increase the immunosuppressive activities of Fingolimod. |
| Flavoxate | Clofarabine may decrease the excretion rate of Flavoxate which could result in a higher serum level. |
| Floctafenine | Floctafenine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Florbetaben (18F) | Clofarabine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. |
| Florbetapir (18F) | Clofarabine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Clofarabine. |
| Fluconazole | Fluconazole may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Flucytosine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Flucytosine. |
| Fludarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fludarabine. |
| Fludeoxyglucose (18F) | Clofarabine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fludrocortisone. |
| Fluindione | The risk or severity of bleeding can be increased when Fluindione is combined with Clofarabine. |
| Flumazenil | Clofarabine may decrease the excretion rate of Flumazenil which could result in a higher serum level. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Clofarabine. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Clofarabine. |
| Fluocinonide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluocinonide. |
| Fluocortolone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluocortolone. |
| Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Clofarabine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Clofarabine. |
| Flupentixol | The risk or severity of myelosuppression can be increased when Flupentixol is combined with Clofarabine. |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluprednisolone. |
| Flurazepam | The serum concentration of Clofarabine can be increased when it is combined with Flurazepam. |
| Flurbiprofen | Flurbiprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Flutamide | Flutamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Fluticasone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluticasone. |
| Fluticasone furoate | The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluticasone furoate. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clofarabine. |
| Fluvoxamine | Fluvoxamine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Folic acid | Folic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Fomepizole | Clofarabine may decrease the excretion rate of Fomepizole which could result in a higher serum level. |
| Fondaparinux | Fondaparinux may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Formestane | Clofarabine may decrease the excretion rate of Formestane which could result in a higher serum level. |
| Foscarnet | Foscarnet may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Fosfomycin | Clofarabine may decrease the excretion rate of Fosfomycin which could result in a higher serum level. |
| Fosinopril | The risk or severity of adverse effects can be increased when Fosinopril is combined with Clofarabine. |
| Fostamatinib | Fostamatinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Fostemsavir | Fostemsavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Framycetin | Framycetin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Furosemide | The excretion of Clofarabine can be decreased when combined with Furosemide. |
| Fusidic acid | Fusidic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Gabapentin enacarbil | Clofarabine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. |
| Gadobenic acid | Clofarabine may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. |
| Gadodiamide | Gadodiamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Gadofosveset trisodium | Clofarabine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. |
| Gadopentetic acid | Clofarabine may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. |
| Gadoteric acid | Clofarabine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. |
| Gadoteridol | Gadoteridol may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Gallium nitrate | The risk or severity of adverse effects can be increased when Clofarabine is combined with Gallium nitrate. |
| Ganciclovir | The excretion of Clofarabine can be decreased when combined with Ganciclovir. |
| Gefitinib | Gefitinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Clofarabine. |
| Gemfibrozil | The excretion of Clofarabine can be decreased when combined with Gemfibrozil. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clofarabine. |
| Gentamicin | Clofarabine may decrease the excretion rate of Gentamicin which could result in a higher serum level. |
| Gilteritinib | Gilteritinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Gimeracil | Clofarabine may decrease the excretion rate of Gimeracil which could result in a higher serum level. |
| Glipizide | Clofarabine may decrease the excretion rate of Glipizide which could result in a higher serum level. |
| Glycerol | Clofarabine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. |
| Golimumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Golimumab. |
| Golodirsen | Clofarabine may decrease the excretion rate of Golodirsen which could result in a higher serum level. |
| Goserelin | Goserelin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Grazoprevir | Grazoprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Grepafloxacin | The serum concentration of Clofarabine can be increased when it is combined with Grepafloxacin. |
| Guanabenz | Clofarabine may increase the hypotensive activities of Guanabenz. |
| Guanadrel | Clofarabine may increase the hypotensive activities of Guanadrel. |
| Guanethidine | Clofarabine may decrease the excretion rate of Guanethidine which could result in a higher serum level. |
| Guanfacine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Guanfacine. |
| Guanidine | The serum concentration of Clofarabine can be increased when it is combined with Guanidine. |
| Guanoxan | Clofarabine may increase the hypotensive activities of Guanoxan. |
| Guselkumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Guselkumab. |
| Haemophilus | The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Clofarabine. |
| Haloperidol | Haloperidol may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Halothane | The risk or severity of adverse effects can be increased when Clofarabine is combined with Halothane. |
| Heparin | The risk or severity of bleeding can be increased when Heparin is combined with Clofarabine. |
| Hepatitis A Vaccine | The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Clofarabine. |
| Hepatitis B Vaccine | The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Clofarabine. |
| Histamine | The serum concentration of Clofarabine can be increased when it is combined with Histamine. |
| Human adenovirus | The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Clofarabine. |
| Hydralazine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydralazine. |
| Hydrochlorothiazide | Hydrochlorothiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone acetate. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone butyrate. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydrocortisone succinate. |
| Hydroflumethiazide | Hydroflumethiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Hydromorphone | Hydromorphone may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Hydroxocobalamin | Hydroxocobalamin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydroxychloroquine. |
| Hydroxyethyl Starch | Clofarabine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydroxyurea. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clofarabine. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ibrutinib. |
| Ibuprofen | The excretion of Clofarabine can be decreased when combined with Ibuprofen. |
| Ibutilide | Ibutilide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Icatibant | Clofarabine may decrease the excretion rate of Icatibant which could result in a higher serum level. |
| Icosapent | Icosapent may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Icosapent ethyl | The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Clofarabine. |
| Idarubicin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Idarubicin. |
| Idarucizumab | Clofarabine may decrease the excretion rate of Idarucizumab which could result in a higher serum level. |
| Idebenone | Clofarabine may decrease the excretion rate of Idebenone which could result in a higher serum level. |
| Idelalisib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Idelalisib. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ifosfamide. |
| Iloprost | The risk or severity of adverse effects can be increased when Clofarabine is combined with Iloprost. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Clofarabine. |
| Imipramine | The serum concentration of Clofarabine can be increased when it is combined with Imipramine. |
| Indapamide | Indapamide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Indigotindisulfonic | Clofarabine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Clofarabine. |
| Indoramin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Indoramin. |
| Inebilizumab | The risk or severity of infection can be increased when Clofarabine is combined with Inebilizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Clofarabine. |
| Kanamycin | Clofarabine may decrease the excretion rate of Kanamycin which could result in a higher serum level. |
| Ketamine | Clofarabine may decrease the excretion rate of Ketamine which could result in a higher serum level. |
| Ketazolam | Clofarabine may decrease the excretion rate of Ketazolam which could result in a higher serum level. |
| Ketoprofen | The excretion of Clofarabine can be decreased when combined with Ketoprofen. |
| Ketorolac | Ketorolac may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with Clofarabine. |
| Lacidipine | Clofarabine may increase the hypotensive activities of Lacidipine. |
| Lamivudine | Clofarabine may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
| Lamotrigine | The serum concentration of Clofarabine can be increased when it is combined with Lamotrigine. |
| Lansoprazole | The excretion of Clofarabine can be decreased when combined with Lansoprazole. |
| Lasmiditan | The serum concentration of Clofarabine can be increased when it is combined with Lasmiditan. |
| Latamoxef | Latamoxef may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ledipasvir | Ledipasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Leflunomide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Clofarabine. |
| Lenvatinib | The serum concentration of Clofarabine can be increased when it is combined with Lenvatinib. |
| Lepirudin | The risk or severity of bleeding can be increased when Lepirudin is combined with Clofarabine. |
| Lercanidipine | The risk or severity of adverse effects can be increased when Lercanidipine is combined with Clofarabine. |
| Lesinurad | Clofarabine may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
| Letermovir | The excretion of Clofarabine can be decreased when combined with Letermovir. |
| Leucovorin | The excretion of Clofarabine can be decreased when combined with Leucovorin. |
| Leuprolide | Leuprolide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Levamlodipine | Clofarabine may increase the hypotensive activities of Levamlodipine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Levobupivacaine. |
| Levocarnitine | Levocarnitine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Levocetirizine | Clofarabine may decrease the excretion rate of Levocetirizine which could result in a higher serum level. |
| Levodopa | The risk or severity of hypotension and orthostatic hypotension can be increased when Clofarabine is combined with Levodopa. |
| Levofloxacin | Clofarabine may decrease the excretion rate of Levofloxacin which could result in a higher serum level. |
| Levoketoconazole | The serum concentration of Clofarabine can be increased when it is combined with Levoketoconazole. |
| Levomilnacipran | Clofarabine may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. |
| Levosalbutamol | Clofarabine may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. |
| Levosimendan | The risk or severity of adverse effects can be increased when Clofarabine is combined with Levosimendan. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Lidocaine. |
| Linagliptin | The serum concentration of Clofarabine can be increased when it is combined with Linagliptin. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Clofarabine. |
| Liothyronine | The excretion of Clofarabine can be decreased when combined with Liothyronine. |
| Liotrix | The excretion of Clofarabine can be decreased when combined with Liotrix. |
| Lipegfilgrastim | Clofarabine may increase the myelosuppressive activities of Lipegfilgrastim. |
| Lisinopril | The risk or severity of adverse effects can be increased when Clofarabine is combined with Lisinopril. |
| Lithium carbonate | Clofarabine may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium citrate | Lithium citrate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Lixisenatide | Clofarabine may decrease the excretion rate of Lixisenatide which could result in a higher serum level. |
| Lofexidine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Lofexidine. |
| Lomustine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Lomustine. |
| Lopinavir | The serum concentration of Clofarabine can be increased when it is combined with Lopinavir. |
| Loracarbef | Loracarbef may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Lorazepam | Lorazepam may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Lorcaserin | Clofarabine may decrease the excretion rate of Lorcaserin which could result in a higher serum level. |
| Lornoxicam | Lornoxicam may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Lorpiprazole | Clofarabine may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. |
| Losartan | The risk or severity of adverse effects can be increased when Clofarabine is combined with Losartan. |
| Loxoprofen | Loxoprofen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Lubiprostone | Clofarabine may decrease the excretion rate of Lubiprostone which could result in a higher serum level. |
| Lumiracoxib | Lumiracoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Macitentan | Clofarabine may decrease the excretion rate of Macitentan which could result in a higher serum level. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Clofarabine. |
| Magnesium carbonate | Clofarabine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. |
| Magnesium chloride | Clofarabine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. |
| Magnesium hydroxide | Clofarabine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
| Magnesium trisilicate | Clofarabine may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. |
| Mangafodipir | Clofarabine may decrease the excretion rate of Mangafodipir which could result in a higher serum level. |
| Manidipine | Clofarabine may increase the hypotensive activities of Manidipine. |
| Mannitol | Mannitol may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Maprotiline | Clofarabine may decrease the excretion rate of Maprotiline which could result in a higher serum level. |
| Maribavir | Maribavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Measles virus vaccine | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Clofarabine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Mecamylamine. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Mechlorethamine. |
| Meclofenamic acid | Meclofenamic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Medroxyprogesterone | Medroxyprogesterone acetate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Mefenamic acid | Mefenamic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Megestrol acetate | Megestrol acetate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Melatonin | The excretion of Clofarabine can be decreased when combined with Melatonin. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Meloxicam. |
| Melphalan | The risk or severity of adverse effects can be increased when Clofarabine is combined with Melphalan. |
| Memantine | Clofarabine may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Clofarabine. |
| Meperidine | Meperidine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Mepolizumab. |
| Meprednisone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Meprednisone. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Mercaptopurine. |
| Meropenem | Clofarabine may decrease the excretion rate of Meropenem which could result in a higher serum level. |
| Mesalazine | Mesalazine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Metamfetamine | Clofarabine may decrease the excretion rate of Metamfetamine which could result in a higher serum level. |
| Metamizole | Metamizole may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Metaxalone | Clofarabine may decrease the excretion rate of Metaxalone which could result in a higher serum level. |
| Metformin | Metformin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Methadone | Methadone may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Naproxen | Naproxen may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Natalizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Natalizumab. |
| Nateglinide | Clofarabine may decrease the excretion rate of Nateglinide which could result in a higher serum level. |
| Nebivolol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nebivolol. |
| Nedaplatin | Clofarabine may decrease the excretion rate of Nedaplatin which could result in a higher serum level. |
| Nedocromil | Clofarabine may decrease the excretion rate of Nedocromil which could result in a higher serum level. |
| Nefazodone | Clofarabine may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
| Nelarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nelarabine. |
| Nelfinavir | Nelfinavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Neomycin | Clofarabine may decrease the excretion rate of Neomycin which could result in a higher serum level. |
| Nesiritide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nesiritide. |
| Netilmicin | Clofarabine may decrease the excretion rate of Netilmicin which could result in a higher serum level. |
| Nialamide | Nialamide may increase the orthostatic hypotensive activities of Clofarabine. |
| Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Clofarabine. |
| Nicorandil | Nicorandil may increase the hypotensive activities of Clofarabine. |
| Nicotine | The serum concentration of Clofarabine can be increased when it is combined with Nicotine. |
| Nifedipine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nifedipine. |
| Nilotinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nilotinib. |
| Nilutamide | Clofarabine may decrease the excretion rate of Nilutamide which could result in a higher serum level. |
| Nilvadipine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nilvadipine. |
| Nimesulide | The risk or severity of bleeding can be increased when Nimesulide is combined with Clofarabine. |
| Nimodipine | The risk or severity of adverse effects can be increased when Nimodipine is combined with Clofarabine. |
| Nisoldipine | The risk or severity of adverse effects can be increased when Nisoldipine is combined with Clofarabine. |
| Nitrendipine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine. |
| Nitric Oxide | The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Clofarabine. |
| Nitrofurantoin | Clofarabine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Nitroglycerin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitroglycerin. |
| Nitroprusside | The risk or severity of adverse effects can be increased when Nitroprusside is combined with Clofarabine. |
| Nitrous acid | The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrous acid. |
| Norepinephrine | The serum concentration of Clofarabine can be increased when it is combined with Norepinephrine. |
| Novobiocin | The excretion of Clofarabine can be decreased when combined with Novobiocin. |
| Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Clofarabine. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Obinutuzumab. |
| Ocrelizumab | Ocrelizumab may increase the immunosuppressive activities of Clofarabine. |
| Octinoxate | Clofarabine may decrease the excretion rate of Octinoxate which could result in a higher serum level. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ofatumumab. |
| Olanzapine | The risk or severity of adverse effects can be increased when Olanzapine is combined with Clofarabine. |
| Olaparib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Olaparib. |
| Olmesartan | The risk or severity of adverse effects can be increased when Olmesartan is combined with Clofarabine. |
| Olsalazine | Olsalazine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Omeprazole | Omeprazole may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Opicapone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Opicapone. |
| Opium | Clofarabine may decrease the excretion rate of Opium which could result in a higher serum level. |
| Oseltamivir | Oseltamivir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Osimertinib | Osimertinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Oteseconazole | The serum concentration of Clofarabine can be increased when it is combined with Oteseconazole. |
| Ouabain | The excretion of Clofarabine can be decreased when combined with Ouabain. |
| Oxacillin | Clofarabine may decrease the excretion rate of Oxacillin which could result in a higher serum level. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Clofarabine. |
| Pantoprazole | The excretion of Clofarabine can be decreased when combined with Pantoprazole. |
| Papaverine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Papaverine. |
| Parecoxib | Parecoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Pargyline | Pargyline may increase the orthostatic hypotensive activities of Clofarabine. |
| Paritaprevir | Paritaprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Parnaparin | The risk or severity of bleeding can be increased when Parnaparin is combined with Clofarabine. |
| Paromomycin | Paromomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Patent Blue | Clofarabine may decrease the excretion rate of Patent Blue which could result in a higher serum level. |
| Pazopanib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Pazopanib. |
| Pegaptanib | Clofarabine may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Clofarabine. |
| Pegcetacoplan | The risk or severity of adverse effects can be increased when Clofarabine is combined with Pegcetacoplan. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Clofarabine. |
| Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clofarabine. |
| Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clofarabine. |
| Peginterferon | The risk or severity of adverse effects can be increased when Clofarabine is combined with Peginterferon beta-1a. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Clofarabine is combined with Pemetrexed. |
| Penbutolol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Penbutolol. |
| Penicillamine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Penicillamine. |
| Pentaerythritol tetranitrate | Clofarabine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. |
| Pentamidine | Pentamidine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Pentastarch | Clofarabine may decrease the excretion rate of Pentastarch which could result in a higher serum level. |
| Pentetic acid | Clofarabine may decrease the excretion rate of Pentetic acid which could result in a higher serum level. |
| Pentobarbital | Pentobarbital may increase the hypotensive activities of Clofarabine. |
| Pentolinium | Clofarabine may increase the hypotensive activities of Pentolinium. |
| Pentosan polysulfate | The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Clofarabine. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Clofarabine. |
| Pentoxifylline | The risk or severity of bleeding can be increased when Pentoxifylline is combined with Clofarabine. |
| Perindopril | The risk or severity of adverse effects can be increased when Clofarabine is combined with Perindopril. |
| Permethrin | Clofarabine may decrease the excretion rate of Permethrin which could result in a higher serum level. |
| Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Clofarabine. |
| Phenazopyridine | Phenazopyridine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Phenelzine | Phenelzine may increase the orthostatic hypotensive activities of Clofarabine. |
| Phenformin | The serum concentration of Clofarabine can be increased when it is combined with Phenformin. |
| Phenindione | The risk or severity of bleeding can be increased when Phenindione is combined with Clofarabine. |
| Phenobarbital | Phenobarbital may increase the hypotensive activities of Clofarabine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Phenol. |
| Phenoxybenzamine | The serum concentration of Clofarabine can be increased when it is combined with Phenoxybenzamine. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Phenprocoumon is combined with Clofarabine. |
| Phentolamine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Phentolamine. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Clofarabine. |
| Phenylbutazone | The excretion of Clofarabine can be decreased when combined with Phenylbutazone. |
| Pholcodine | Clofarabine may decrease the excretion rate of Pholcodine which could result in a higher serum level. |
| Phosphoric acid | Clofarabine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. |
| Phylloquinone | Clofarabine may decrease the excretion rate of Phylloquinone which could result in a higher serum level. |
| Pibrentasvir | Pibrentasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Picosulfuric acid | Clofarabine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clofarabine. |
| Pinacidil | Clofarabine may increase the hypotensive activities of Pinacidil. |
| Pindolol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Pindolol. |
| Piperacillin | Piperacillin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Piracetam | Clofarabine may decrease the excretion rate of Piracetam which could result in a higher serum level. |
| Piretanide | Piretanide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Pirfenidone. |
| Piroxicam | The excretion of Clofarabine can be decreased when combined with Piroxicam. |
| Pitolisant | Clofarabine may decrease the excretion rate of Pitolisant which could result in a higher serum level. |
| Plazomicin | Clofarabine may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
| Plerixafor | Clofarabine may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
| Polythiazide | Polythiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Pomalidomide. |
| Ponatinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ponatinib. |
| Ponesimod | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ponesimod. |
| Potassium | Potassium may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium acetate | Clofarabine may decrease the excretion rate of Potassium acetate which could result in a higher serum level. |
| Potassium bicarbonate | Clofarabine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. |
| Potassium cation | Potassium cation may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium chloride | Clofarabine may decrease the excretion rate of Potassium chloride which could result in a higher serum level. |
| Potassium citrate | Potassium citrate may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Potassium nitrate | Clofarabine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. |
| Potassium perchlorate | Clofarabine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. |
| Potassium sulfate | Clofarabine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. |
| Practolol | Clofarabine may increase the hypotensive activities of Practolol. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Clofarabine is combined with Pralatrexate. |
| Pralidoxime | Clofarabine may decrease the excretion rate of Pralidoxime which could result in a higher serum level. |
| Pralsetinib | Pralsetinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Pramipexole | The risk or severity of adverse effects can be increased when Pramipexole is combined with Clofarabine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Pramocaine. |
| Prasugrel | The risk or severity of bleeding can be increased when Prasugrel is combined with Clofarabine. |
| Pravastatin | The excretion of Clofarabine can be decreased when combined with Pravastatin. |
| Prazosin | The risk or severity of adverse effects can be increased when Prazosin is combined with Clofarabine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Prednisolone. |
| Prednisone | The risk or severity of adverse effects can be increased when Clofarabine is combined with Prednisone. |
| Pregabalin | Pregabalin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Prilocaine. |
| Primidone | Primidone may increase the hypotensive activities of Clofarabine. |
| Probenecid | The serum concentration of Clofarabine can be increased when it is combined with Probenecid. |
| Procainamide | The serum concentration of Clofarabine can be increased when it is combined with Procainamide. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Procaine. |
| Procaine | Clofarabine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
| Procarbazine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Procarbazine. |
| Progesterone | The serum concentration of Clofarabine can be increased when it is combined with Progesterone. |
| Promethazine | Clofarabine may decrease the excretion rate of Promethazine which could result in a higher serum level. |
| Propantheline | Clofarabine may decrease the excretion rate of Propantheline which could result in a higher serum level. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Proparacaine. |
| Propiverine | Clofarabine may decrease the excretion rate of Propiverine which could result in a higher serum level. |
| Propofol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Propofol. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Propoxycaine. |
| Propranolol | The serum concentration of Clofarabine can be increased when it is combined with Propranolol. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Clofarabine. |
| Protein C | The risk or severity of bleeding can be increased when Protein C is combined with Clofarabine. |
| Protein S human | The risk or severity of bleeding can be increased when Protein S human is combined with Clofarabine. |
| Prucalopride | Clofarabine may decrease the excretion rate of Prucalopride which could result in a higher serum level. |
| Pyrantel | Clofarabine may decrease the excretion rate of Pyrantel which could result in a higher serum level. |
| Pyrazinamide | Pyrazinamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Pyridoxine | Pyridoxine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Pyrithione | Clofarabine may decrease the excretion rate of Pyrithione which could result in a higher serum level. |
| Quetiapine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Quetiapine. |
| Quinapril | The risk or severity of adverse effects can be increased when Clofarabine is combined with Quinapril. |
| Quinethazone | Quinethazone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Quinidine | The serum concentration of Clofarabine can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Clofarabine can be increased when it is combined with Quinine. |
| Rabeprazole | Rabeprazole may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Rabies immune | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Clofarabine. |
| Rabies virus | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Clofarabine. |
| Rabies virus inactivated | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Clofarabine. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Clofarabine. |
| Ramelteon | Clofarabine may decrease the excretion rate of Ramelteon which could result in a higher serum level. |
| Ramipril | The risk or severity of adverse effects can be increased when Ramipril is combined with Clofarabine. |
| Ranitidine | The serum concentration of Clofarabine can be increased when it is combined with Ranitidine. |
| Ranolazine | The serum concentration of Clofarabine can be increased when it is combined with Ranolazine. |
| Rasagiline | Rasagiline may increase the orthostatic hypotensive activities of Clofarabine. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ravulizumab. |
| Regorafenib | Regorafenib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Remifentanil | The risk or severity of adverse effects can be increased when Clofarabine is combined with Remifentanil. |
| Rescinnamine | Clofarabine may increase the hypotensive activities of Rescinnamine. |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Clofarabine. |
| Resorcinol | Clofarabine may decrease the excretion rate of Resorcinol which could result in a higher serum level. |
| Reteplase | The risk or severity of bleeding can be increased when Reteplase is combined with Clofarabine. |
| Reviparin | The risk or severity of bleeding can be increased when Reviparin is combined with Clofarabine. |
| Ribavirin | Clofarabine may decrease the excretion rate of Ribavirin which could result in a higher serum level. |
| Ribostamycin | Clofarabine may decrease the excretion rate of Ribostamycin which could result in a higher serum level. |
| Rifampicin | The excretion of Clofarabine can be decreased when combined with Rifampicin. |
| Rilmenidine | Clofarabine may increase the hypotensive activities of Rilmenidine. |
| Rilonacept | The risk or severity of adverse effects can be increased when Clofarabine is combined with Rilonacept. |
| Rilpivirine | Rilpivirine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Riociguat | The risk or severity of adverse effects can be increased when Clofarabine is combined with Riociguat. |
| Ripretinib | Ripretinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Risankizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Risankizumab. |
| Risperidone | Clofarabine may increase the hypotensive activities of Risperidone. |
| Ritonavir | Ritonavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Clofarabine. |
| Rivaroxaban | Clofarabine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
| Rizatriptan | Clofarabine may decrease the excretion rate of Rizatriptan which could result in a higher serum level. |
| Rofecoxib | Rofecoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Clofarabine. |
| Rolapitant | Rolapitant may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ropeginterferon | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ropeginterferon alfa-2b. |
| Ropinirole | The risk or severity of adverse effects can be increased when Ropinirole is combined with Clofarabine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Ropivacaine. |
| Rosiglitazone | Rosiglitazone may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Rosuvastatin | The excretion of Clofarabine can be decreased when combined with Rosuvastatin. |
| Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Clofarabine. |
| Rotigotine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Rotigotine. |
| Roxadustat | The serum concentration of Clofarabine can be increased when it is combined with Roxadustat. |
| Rubella virus vaccine | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Clofarabine. |
| Rucaparib | Rucaparib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ruxolitinib. |
| Sacubitril | The risk or severity of adverse effects can be increased when Clofarabine is combined with Sacubitril. |
| Safinamide | Safinamide may increase the orthostatic hypotensive activities of Clofarabine. |
| Salbutamol | Clofarabine may decrease the excretion rate of Salbutamol which could result in a higher serum level. |
| Salicylamide | Salicylamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Salicylic acid | The excretion of Clofarabine can be decreased when combined with Salicylic acid. |
| Salmeterol | The serum concentration of Clofarabine can be increased when it is combined with Salmeterol. |
| Salmon calcitonin | Salmon calcitonin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Salsalate | Salsalate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Saquinavir | Saquinavir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Sarilumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Sarilumab. |
| Satralizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Satralizumab. |
| Saxagliptin | Clofarabine may decrease the excretion rate of Saxagliptin which could result in a higher serum level. |
| Secobarbital | Secobarbital may increase the hypotensive activities of Clofarabine. |
| Secukinumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Secukinumab. |
| Selegiline | Selegiline may increase the orthostatic hypotensive activities of Clofarabine. |
| Selenious acid | Clofarabine may decrease the excretion rate of Selenious acid which could result in a higher serum level. |
| Selenium | Clofarabine may decrease the excretion rate of Selenium which could result in a higher serum level. |
| Selexipag | Clofarabine may increase the hypotensive activities of Selexipag. |
| Sevoflurane | The risk or severity of adverse effects can be increased when Clofarabine is combined with Sevoflurane. |
| Sibutramine | Clofarabine may decrease the excretion rate of Sibutramine which could result in a higher serum level. |
| Sildenafil | The risk or severity of hypotension can be increased when Sildenafil is combined with Clofarabine. |
| Siltuximab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Siltuximab. |
| Simeprevir | Simeprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Siponimod | The risk or severity of adverse effects can be increased when Clofarabine is combined with Siponimod. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Clofarabine. |
| Sirolimus | The risk or severity of adverse effects can be increased when Clofarabine is combined with Sirolimus. |
| Sitagliptin | Clofarabine may decrease the excretion rate of Sitagliptin which could result in a higher serum level. |
| Sitaxentan | Clofarabine may increase the hypotensive activities of Sitaxentan. |
| Smallpox | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Clofarabine. |
| Sodium acetate | Clofarabine may decrease the excretion rate of Sodium acetate which could result in a higher serum level. |
| Sodium aurothiomalate | Clofarabine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. |
| Sodium citrate | The risk or severity of bleeding can be increased when Sodium citrate is combined with Clofarabine. |
| Sodium ferric | The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Clofarabine. |
| Sodium fluoride | Clofarabine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. |
| Sodium sulfate | Clofarabine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. |
| Sofosbuvir | Clofarabine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
| Solriamfetol | Clofarabine may decrease the excretion rate of Solriamfetol which could result in a higher serum level. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with Clofarabine. |
| Sorbitol | Clofarabine may decrease the excretion rate of Sorbitol which could result in a higher serum level. |
| Sotagliflozin | Sotagliflozin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with Clofarabine. |
| Spesolimab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Spesolimab. |
| Spirapril | Clofarabine may increase the hypotensive activities of Spirapril. |
| Spironolactone | Spironolactone may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Stiripentol | The excretion of Clofarabine can be decreased when combined with Stiripentol. |
| Streptokinase | The risk or severity of adverse effects can be increased when Streptokinase is combined with Clofarabine. |
| Streptomycin | Clofarabine may decrease the excretion rate of Streptomycin which could result in a higher serum level. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Clofarabine. |
| Strontium chloride | Clofarabine may decrease the excretion rate of Strontium chloride which could result in a higher serum level. |
| Sucralfate | Sucralfate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Sufentanil | The risk or severity of adverse effects can be increased when Clofarabine is combined with Sufentanil. |
| Sulbactam | Clofarabine may decrease the excretion rate of Sulbactam which could result in a higher serum level. |
| Sulfadiazine | Sulfadiazine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Clofarabine. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Sulfasalazine. |
| Sulfinpyrazone | The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Clofarabine. |
| Sulindac | Sulindac may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Sulodexide | The risk or severity of bleeding can be increased when Sulodexide is combined with Clofarabine. |
| Sumatriptan | Clofarabine may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
| Sunitinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Sunitinib. |
| Estrogens, A | Clofarabine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. |
| Synthetic Conjugated | Clofarabine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. |
| Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Clofarabine. |
| Tadalafil | Clofarabine may decrease the excretion rate of Tadalafil which could result in a higher serum level. |
| Tafamidis | The serum concentration of Clofarabine can be increased when it is combined with Tafamidis. |
| Tafenoquine | The serum concentration of Clofarabine can be increased when it is combined with Tafenoquine. |
| Tamsulosin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Tamsulosin. |
| Tasimelteon | Clofarabine may decrease the excretion rate of Tasimelteon which could result in a higher serum level. |
| Taurocholic acid | The excretion of Clofarabine can be decreased when combined with Taurocholic acid. |
| Tazobactam | The excretion of Clofarabine can be decreased when combined with Tazobactam. |
| Technetium | Clofarabine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. |
| Technetium | Clofarabine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. |
| Technetium | Clofarabine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. |
| Technetium | Clofarabine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. |
| Tedizolid phosphate | The risk or severity of myelosuppression can be increased when Clofarabine is combined with Tedizolid phosphate. |
| Teduglutide | Clofarabine may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
| Tegafur | Clofarabine may decrease the excretion rate of Tegafur which could result in a higher serum level. |
| Telavancin | Clofarabine may decrease the excretion rate of Telavancin which could result in a higher serum level. |
| Telmisartan | Telmisartan may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Temazepam | Temazepam may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Temozolomide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Temozolomide. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Clofarabine is combined with Temsirolimus. |
| Tenecteplase | The risk or severity of bleeding can be increased when Tenecteplase is combined with Clofarabine. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Clofarabine. |
| Tenofovir alafenamide | Tenofovir alafenamide may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Tenofovir disoproxil | Tenofovir disoproxil may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Tenoxicam | The excretion of Clofarabine can be decreased when combined with Tenoxicam. |
| Tepotinib | Tepotinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Teprotumumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Teprotumumab. |
| Terazosin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Terazosin. |
| Terbutaline | Clofarabine may decrease the excretion rate of Terbutaline which could result in a higher serum level. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Teriflunomide. |
| Testolactone | Clofarabine may decrease the excretion rate of Testolactone which could result in a higher serum level. |
| Testosterone | The excretion of Clofarabine can be increased when combined with Testosterone. |
| Testosterone | The excretion of Clofarabine can be increased when combined with Testosterone cypionate. |
| Testosterone | The excretion of Clofarabine can be increased when combined with Testosterone enanthate. |
| Testosterone | Clofarabine may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. |
| Testosterone | Clofarabine may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Tetracaine. |
| Tetracycline | The excretion of Clofarabine can be decreased when combined with Tetracycline. |
| Tetradecyl hydrogen ) | Clofarabine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. |
| Thalidomide | The risk or severity of adverse effects can be increased when Clofarabine is combined with Thalidomide. |
| Thiabendazole | Clofarabine may decrease the excretion rate of Thiabendazole which could result in a higher serum level. |
| Thiamine | The serum concentration of Clofarabine can be increased when it is combined with Thiamine. |
| Thiamylal | Thiamylal may increase the hypotensive activities of Clofarabine. |
| Thiethylperazine | Thiethylperazine may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Thiopental | Thiopental may increase the hypotensive activities of Clofarabine. |
| Thioridazine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Thioridazine. |
| Thiotepa | The risk or severity of adverse effects can be increased when Clofarabine is combined with Thiotepa. |
| Tiaprofenic acid | Tiaprofenic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Ticagrelor | The risk or severity of bleeding can be increased when Ticagrelor is combined with Clofarabine. |
| Tick-borne encephalitis | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Clofarabine. |
| Ticlopidine | The risk or severity of bleeding can be increased when Ticlopidine is combined with Clofarabine. |
| Tiludronic acid | Clofarabine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. |
| Timolol | The risk or severity of adverse effects can be increased when Timolol is combined with Clofarabine. |
| Tinidazole | Clofarabine may decrease the excretion rate of Tinidazole which could result in a higher serum level. |
| Tinzaparin | The risk or severity of bleeding can be increased when Tinzaparin is combined with Clofarabine. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Clofarabine. |
| Tiopronin | Clofarabine may decrease the excretion rate of Tiopronin which could result in a higher serum level. |
| Tiotropium | Clofarabine may decrease the excretion rate of Tiotropium which could result in a higher serum level. |
| Tirofiban | The risk or severity of bleeding can be increased when Tirofiban is combined with Clofarabine. |
| Tivozanib | Tivozanib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Tixocortol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Tixocortol. |
| Tizanidine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Tizanidine. |
| Tobramycin | Clofarabine may decrease the excretion rate of Tobramycin which could result in a higher serum level. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Tocilizumab. |
| Tocopherol | Clofarabine may decrease the excretion rate of Tocopherol which could result in a higher serum level. |
| Tofacitinib | Clofarabine may increase the immunosuppressive activities of Tofacitinib. |
| Tolazamide | Clofarabine may decrease the excretion rate of Tolazamide which could result in a higher serum level. |
| Tolazoline | The risk or severity of adverse effects can be increased when Clofarabine is combined with Tolazoline. |
| Tolbutamide | Clofarabine may decrease the excretion rate of Tolbutamide which could result in a higher serum level. |
| Tolcapone | The risk or severity of adverse effects can be increased when Tolcapone is combined with Clofarabine. |
| Tolfenamic acid | Tolfenamic acid may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Tolmetin | Tolmetin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Tolterodine | Clofarabine may decrease the excretion rate of Tolterodine which could result in a higher serum level. |
| Tolvaptan | Tolvaptan may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Topiramate | Topiramate may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Topotecan | The risk or severity of adverse effects can be increased when Clofarabine is combined with Topotecan. |
| Torasemide | Torasemide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Clofarabine. |
| Trabectedin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Trabectedin. |
| Tramadol | Tramadol may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Trametinib | Clofarabine may decrease the excretion rate of Trametinib which could result in a higher serum level. |
| Trandolapril | The risk or severity of adverse effects can be increased when Trandolapril is combined with Clofarabine. |
| Tranylcypromine | Tranylcypromine may increase the orthostatic hypotensive activities of Clofarabine. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Clofarabine. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Trastuzumab emtansine. |
| Treprostinil | Clofarabine may increase the hypotensive activities of Treprostinil. |
| Tretinoin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Tretinoin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Clofarabine. |
| Triamterene | Triamterene may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Triazolam | Clofarabine may decrease the excretion rate of Triazolam which could result in a higher serum level. |
| Trichlormethiazide | Trichlormethiazide may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Triethylenetetramine | Clofarabine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Clofarabine. |
| Triflusal | The risk or severity of bleeding can be increased when Triflusal is combined with Clofarabine. |
| Trilaciclib | The serum concentration of Clofarabine can be increased when it is combined with Trilaciclib. |
| Trilostane | The risk or severity of adverse effects can be increased when Clofarabine is combined with Trilostane. |
| Trimebutine | Clofarabine may decrease the excretion rate of Trimebutine which could result in a higher serum level. |
| Trimethaphan | Clofarabine may increase the hypotensive activities of Trimethaphan. |
| Trimethoprim | The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim. |
| Trimetrexate | Clofarabine may decrease the excretion rate of Trimetrexate which could result in a higher serum level. |
| Tropisetron | Clofarabine may decrease the excretion rate of Tropisetron which could result in a higher serum level. |
| Tucatinib | The serum concentration of Clofarabine can be increased when it is combined with Tucatinib. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Clofarabine. |
| Typhoid Vaccine | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Clofarabine. |
| Typhoid Vi | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Clofarabine. |
| Udenafil | The risk or severity of hypotension can be increased when Udenafil is combined with Clofarabine. |
| Upadacitinib | The risk or severity of adverse effects can be increased when Clofarabine is combined with Upadacitinib. |
| Urokinase | The risk or severity of bleeding can be increased when Urokinase is combined with Clofarabine. |
| Vaborbactam | Clofarabine may decrease the excretion rate of Vaborbactam which could result in a higher serum level. |
| Valaciclovir | Valaciclovir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Valbenazine | Clofarabine may decrease the excretion rate of Valbenazine which could result in a higher serum level. |
| Valdecoxib | Valdecoxib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Valganciclovir | Clofarabine may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
| Valproic acid | The excretion of Clofarabine can be decreased when combined with Valproic acid. |
| Valsartan | The risk or severity of adverse effects can be increased when Valsartan is combined with Clofarabine. |
| Vancomycin | Clofarabine may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
| Vandetanib | The serum concentration of Clofarabine can be increased when it is combined with Vandetanib. |
| Vardenafil | The risk or severity of hypotension can be increased when Vardenafil is combined with Clofarabine. |
| Varenicline | The serum concentration of Clofarabine can be increased when it is combined with Varenicline. |
| Varicella zoster | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Clofarabine. |
| Varicella zoster | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Clofarabine. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Clofarabine is combined with Vedolizumab. |
| Velpatasvir | Velpatasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Vemurafenib | Vemurafenib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Venetoclax | Venetoclax may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Venlafaxine | Venlafaxine may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy. |
| Verapamil | The risk or severity of adverse effects can be increased when Clofarabine is combined with Verapamil. |
| Vericiguat | The risk or severity of adverse effects can be increased when Clofarabine is combined with Vericiguat. |
| Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Clofarabine. |
| Vilanterol | The risk or severity of adverse effects can be increased when Clofarabine is combined with Vilanterol. |
| Viloxazine | Clofarabine may decrease the excretion rate of Viloxazine which could result in a higher serum level. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with Clofarabine. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Clofarabine. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Clofarabine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Clofarabine. |
| Vismodegib | Vismodegib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Voclosporin | The risk or severity of adverse effects can be increased when Clofarabine is combined with Voclosporin. |
| Vorapaxar | The risk or severity of bleeding can be increased when Vorapaxar is combined with Clofarabine. |
| Vorinostat | The risk or severity of adverse effects can be increased when Clofarabine is combined with Vorinostat. |
| Vortioxetine | Clofarabine may decrease the excretion rate of Vortioxetine which could result in a higher serum level. |
| Voxilaprevir | Voxilaprevir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Warfarin | Clofarabine may decrease the excretion rate of Warfarin which could result in a higher serum level. |
Pregnancy and Lactation
FDA Pregnancy Category D
Pregnancy
Collar (clofarabine) may cause fetal harm when administered to a pregnant woman. Clofarabine was teratogenic in rats and rabbits. Developmental toxicity (reduced fetal body weight and increased post-implantation loss) and increased incidences of malformations and
variations (gross external, soft tissue, skeletal and retarded ossification) were observed in rats receiving 54 mg/m2 /day (approximately equivalent to the recommended clinical dose on an mg/m2 basis), and in rabbits receiving 12 mg/m2 /day (approximately 23% of the recommended clinical dose on an mg/m2 basis). There are no adequate and well-controlled studies on pregnant women using clofarabine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving
treatment with clofarabine. All patients should be advised to use effective contraceptive measures to prevent pregnancy.
Lactation
It is not known whether clofarabine or its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for clofarabine in animal studies and the potential for serious adverse reactions, women treated with clofarabine should not nurse. Female patients should be advised to avoid breastfeeding during treatment with Clolar.
How should this medicine be used?
Clofarabine comes as a solution to be injected into a vein. Clofarabine is administered by a doctor or nurse. It is usually given once a day for 5 days in a row. This dosing cycle may be repeated once every 2 to 6 weeks, depending on your response to the medication.
It will take at least 2 hours for you to receive each dose of clofarabine. Tell your doctor or another healthcare provider right away if you feel anxious or restless while you are receiving the medication.
What special precautions should I follow?
Before using clofarabine,
- tell your doctor and pharmacist if you are allergic to clofarabine or any other medications.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention medications for high blood pressure and heart disease. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had kidney or liver disease.
- tell your doctor if you are pregnant or plan to become pregnant. Clofarabine may harm the fetus. You should use birth control to prevent pregnancy during your treatment with clofarabine. Talk to your doctor about the types of birth control that will work for you. If you become pregnant while using clofarabine, call your doctor.
- tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with clofarabine.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving clofarabine.
- you should know that clofarabine may cause a skin condition called hand-foot syndrome. If you develop this condition, you may experience tingling of the hands and feet, and then reddening dryness, and flaking of the skin on the hands and feet. If this happens, ask your doctor to recommend a lotion that you can apply to these areas. You will need to apply the lotion lightly and avoid rubbing the areas forcefully. Your doctor may also prescribe medication to relieve these symptoms.
References
